5,376 Shares in Henry Schein, Inc. (NASDAQ:HSIC) Purchased by Stevens Capital Management LP

Stevens Capital Management LP bought a new stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,376 shares of the company's stock, valued at approximately $372,000.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its position in shares of Henry Schein by 23.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after purchasing an additional 143 shares during the period. CIBC Asset Management Inc raised its holdings in Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after buying an additional 169 shares during the last quarter. Metis Global Partners LLC lifted its stake in shares of Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock valued at $291,000 after buying an additional 187 shares in the last quarter. Central Pacific Bank Trust Division grew its holdings in shares of Henry Schein by 2.0% during the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company's stock valued at $706,000 after buying an additional 200 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its position in shares of Henry Schein by 5.0% during the fourth quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company's stock worth $294,000 after acquiring an additional 203 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Henry Schein Stock Performance

NASDAQ HSIC traded down $0.78 during trading hours on Friday, reaching $68.62. 1,028,798 shares of the company were exchanged, compared to its average volume of 1,573,330. The stock has a market capitalization of $8.52 billion, a P/E ratio of 28.24, a P/E/G ratio of 2.13 and a beta of 0.90. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Henry Schein, Inc. has a 1 year low of $63.67 and a 1 year high of $82.49. The business's 50 day simple moving average is $74.62 and its 200-day simple moving average is $72.60.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company had revenue of $3.19 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same quarter in the previous year, the business earned $0.66 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Insider Activity

In other news, Director Philip A. Laskawy sold 2,604 shares of Henry Schein stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now owns 24,805 shares in the company, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bradford C. Connett sold 4,036 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares in the company, valued at approximately $4,460,251.20. This trade represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company's stock.

Analysts Set New Price Targets

HSIC has been the subject of a number of analyst reports. Mizuho started coverage on Henry Schein in a research note on Wednesday, December 4th. They set a "neutral" rating and a $75.00 price target for the company. Barrington Research reaffirmed an "outperform" rating and set a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Bank of America raised Henry Schein from an "underperform" rating to a "buy" rating and increased their price target for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Jefferies Financial Group lifted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. Finally, UBS Group lowered their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a report on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $81.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.